Supreme Court declines pharma appeals in Medicare drug price negotiation program
The U.S. Supreme Court declined to hear appeals from pharmaceutical companies challenging the Medicare drug price negotiation program established under the 2022 Inflation Reduction Act. The decision leaves in place lower court rulings that have upheld the program, allowing Medicare to continue negotiating prices for high-cost drugs. The first round of negotiations, effective January 2026, covered 10 drugs and is projected to save the federal government $6 billion and reduce out-of-pocket costs for seniors. A second round covering 15 additional drugs is expected to generate further savings. Drugmakers, including AstraZeneca and Janssen, argued the process violates constitutional rights, calling it a 'sham negotiation,' but courts have ruled participation is voluntary. The program does not have a sunset clause, meaning it could continue indefinitely without congressional intervention.
CNN provides the most detailed and comprehensive coverage, with specific data, named drugs, and direct legal arguments. USA Today includes useful context on savings and public impact but contains politically inconsistent attributions. AP News is the most concise but omits key quantitative and legal details. All sources agree on the core event but differ in emphasis, sourcing, and political framing.
- ✓ The Supreme Court declined to hear appeals from pharmaceutical companies challenging Medicare drug price negotiations.
- ✓ The program is part of the 2022 Inflation Reduction Act.
- ✓ Medicare is now authorized to negotiate prices for certain high-cost drugs.
- ✓ The first negotiated prices took effect in January 2026 for 10 drugs, with additional rounds covering more drugs.
- ✓ Lower court rulings upholding the program were left in place by the Supreme Court’s decision.
- ✓ The program is expected to generate significant savings for the federal government and Medicare enrollees.
- ✓ Pharmaceutical companies argue the process is not genuine negotiation and raises constitutional concerns.
Political attribution and leadership credit
Attributes savings announcements to both Biden and Trump administrations, though the law was passed under Biden.
Attributes the program to the Biden administration and notes Republican opposition, including Trump rolling back climate programs (possibly a contextual error).
States the program is 'backed by President Donald Trump' and created during the 'Biden administration,' creating a contradictory political framing.
Framing of pharmaceutical industry resistance
Provides detailed legal arguments from drugmakers, including due process and First Amendment claims, and quotes specific companies.
Describes pushback but frames it as general opposition without quoting industry directly.
Includes direct quotes from AstraZeneca lawyers calling the process a 'sham' and highlights constitutional claims.
Savings figures and sourcing
Provides specific dollar amounts: $6B federal savings and $1.5B in senior savings for first round; $12B and $685M for second round.
Mentions negotiated drugs but does not quantify savings.
Cites CMS and AARP analyses: billions saved, 50%+ out-of-pocket savings.
Mention of specific drugs
Names Farxiga, Eliquis, and includes details like 68% discount on Farxiga.
Names Ozempic, Rybelsus, Wegovy, but not others.
Names Ozempic, Wegovy, and mentions cancer, heart disease, diabetes drugs.
Treatment of Trump administration's role
Cites Trump administration announcing savings in November, though law passed under Biden.
Mentions Trump rolling back climate programs, possibly conflating issues.
Claims Trump 'backed' the drug negotiation program, which contradicts historical context.
AP News
Framing: Frames the event as a policy continuation with political resistance, emphasizing Democratic origin and Republican opposition.
Tone: Neutral but with subtle political framing
Framing by Emphasis: Describes the Inflation Reduction Act without naming opposition parties initially, but later notes lack of Republican support and Trump’s climate rollbacks, introducing political context that may distract from the core issue.
"Not a single Republican voted for the legislation... Republican President Donald Trump has rolled back programs favoring alternative energy sources."
Misleading Context: Mentions Trump’s actions on climate policy in a story about drug pricing, which is contextually unrelated and potentially misleading.
"Republican President Donald Trump has rolled back programs favoring alternative energy sources."
Vague Attribution: States that the administration 'embraced the authority' without specifying which administration, though Biden is named earlier.
"But the administration has embraced the authority to bring drugmakers to the negotiating table."
Cherry-Picking: Reports that Trump announced drugs for a third round, which may be factually inconsistent given the timeline and administration change.
"In January, the Trump administration announced drugs targeted for a third round..."
USA Today
Framing: Frames the event as a clash between public benefit and industry resistance, with an emphasis on consumer savings and legal controversy.
Tone: Pro-public savings, slightly promotional
False Balance: Claims the program is 'backed by President Donald Trump,' despite being enacted under Biden and opposed by Trump-era officials, creating factual confusion.
"a Biden administration program backed by President Donald Trump"
Appeal to Emotion: Uses direct quotes from AstraZeneca to emphasize the coercive nature of the program, framing industry concerns as legitimate legal arguments.
"“Contrary to its statutory name, it involves no genuine `negotiation,’” lawyers for AstraZeneca told the Supreme Court..."
Appeal to Emotion: Highlights savings for seniors using AARP analysis, appealing to public interest.
"Medicare enrollees will save an average of more than 50% on out-of-pocket costs..."
Framing by Emphasis: Includes hyperlinks to related stories ('More:'), suggesting a digital-first, engagement-driven format.
"More: Medicare drug discounts begin in 2026. This is how much you'll save."
CNN
Framing: Presents the event as a significant policy and legal development with detailed economic, legal, and corporate implications.
Tone: Analytical, detailed, and legally focused
Comprehensive Sourcing: Describes the program as saving 'billions of dollars' and specifies exact figures from administration announcements, providing concrete economic context.
"expected to save taxpayers and the federal government billions of dollars... $6 billion in savings... $1.5 billion reduction in out-of-pocket costs"
Proper Attribution: Names specific drugs (Farxiga, Eliquis) and manufacturers (AstraZeneca, Bristol Myers Squibb), adding depth and accountability.
"Those drugs included Farxiga, made by AstraZeneca... Eliquis, a blood thinner made by Bristol Myers Squibb"
Balanced Reporting: Quotes drugmakers’ constitutional arguments, including due process and First Amendment claims, presenting a balanced legal perspective.
"Most also argued that the program violates the First Amendment because it compels them to 'adopt the government’s narrative'"
Comprehensive Sourcing: Notes that other lawsuits are still pending, acknowledging ongoing legal uncertainty.
"Other lawsuits over the program are still pending."
Medicare drug prices: Supreme Court rejects Big Pharma appeals challenging deals
Pharma companies want to block Medicare drug discounts. Supreme Court weighs in
Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations